Novan announces publication of psoriasis patient data

Novan and MC2 Therapeutics announced that results of a recently conducted survey to assess psoriasis patients’ topical treatment experience, expectations, and preferences have been published in the Journal of Drugs in Dermatology, JDD. The survey was conducted by the National Psoriasis Foundation and was sponsored by the Company. Most of the participants self-reported having moderate psoriasis; most were using systemic therapies and employing topical medications at least once per week. Key findings from the published results of the conducted survey include: More than 90% of respondents stated they suffered from itch frequently or always, with the majority of them rating this as moderate, severe or very severe, and most often affecting the scalp, elbows and arms, and trunk. Nearly 80% of participants in the survey said they would discontinue a topical treatment if they did not notice an improvement in their symptoms in two weeks or less. 40% of patients stated they would call a different dermatologist if a treatment they were prescribed caused an unwanted reaction. 75% of participants stated they would only use a medication for a week if they did not like a formulation that was prescribed for them.